Segal Trials, a clinical research network specializing in psychiatric disorders, significantly contributed to the successful Phase 2 trial of LB-102, a novel antipsychotic for acute schizophrenia. The trial, sponsored by LB Pharmaceuticals, met its primary endpoint, demonstrating the drug’s efficacy, safety, and tolerability. Two Segal Trials investigators enrolled 18% of the total study participants, exceeding their enrollment goal by 47%.
This success underscores the potential of LB-102 to address the unmet needs of schizophrenia patients who experience inadequate symptom control or intolerable side effects with existing medications. The positive results could lead to a much-needed new treatment option for this debilitating condition. Segal Trials’ high enrollment rate highlights the efficacy of their community-based outreach and patient-centric approach, a model that could influence how other research networks recruit for complex psychiatric trials.
Segal Trials randomized eight subjects per month over seven months, showcasing their specialized research infrastructure and expertise in acute schizophrenia. Their dedicated 10,000 sq ft. Miami Lakes Medical Research facility, designed for complex trials, has enrolled over 800 subjects across 50 trials since 2019. This facility allows for the segregation of special populations and adaptable configurations for various study designs.
LB Pharmaceuticals plans to discuss Phase 3 trial design with the FDA by early 2026. This positive development suggests a potential shift in the treatment landscape for schizophrenia, offering hope for improved outcomes for a significant portion of the global population affected by this disorder. The success of LB-102’s Phase 2 trial, coupled with Segal Trials’ continued enrollment efforts, positions both organizations for continued progress in advancing schizophrenia research and treatment.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
